Medications for Lung Disease: Bronchodilators, Steroids, and Biologics

Pharmacological management of lung disease spans a wide range of drug classes, each targeting distinct mechanisms in airway obstruction, inflammation, and immune dysregulation. This page covers the three dominant categories — bronchodilators, corticosteroids, and biologic agents — along with their mechanisms, clinical applications, and the decision logic that guides their use. Understanding these distinctions matters because inappropriate class selection is a named driver of poor outcomes in conditions such as COPD and asthma, both of which carry significant disease burden across the United States.

Definition and Scope

Medications for chronic and acute lung disease fall into three major pharmacological classes, each defined by mechanism and target tissue:

The U.S. Food and Drug Administration (FDA) regulates approval and labeling for each class under 21 CFR Parts 312 and 314. Drug scheduling, safety monitoring, and Risk Evaluation and Mitigation Strategies (REMS) requirements apply to specific agents within these classes. A broader orientation to how treatment decisions fit within clinical oversight is covered in regulatory context for pulmonary medicine.

Inhaled delivery is the predominant route for bronchodilators and corticosteroids, a preference endorsed by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) and the Global Initiative for Asthma (GINA) because it maximizes local drug concentration while minimizing systemic exposure. Biologics are administered systemically — subcutaneously or intravenously — due to their molecular size and mechanism.

How It Works

Bronchodilators

Bronchodilators divide into three mechanistic subclasses:

  1. Short-acting beta-2 agonists (SABAs) — bind beta-2 adrenergic receptors on bronchial smooth muscle, activating adenylyl cyclase and elevating cyclic AMP. This cascade triggers smooth muscle relaxation within 5–15 minutes. Albuterol is the most widely used SABA in the United States.

  2. Long-acting beta-2 agonists (LABAs) — share the same receptor pathway but have molecular structures conferring 12–24 hours of receptor binding. Formoterol and salmeterol are the principal LABA agents. The FDA requires that LABAs for asthma be used only in combination with an inhaled corticosteroid (ICS), a safety constraint codified in updated prescribing labels following post-market safety analyses.

  3. Long-acting muscarinic antagonists (LAMAs) — block M3 muscarinic receptors on airway smooth muscle and submucosal glands, reducing bronchoconstriction and mucus hypersecretion. Tiotropium, approved by the FDA in 2004, remains a first-line maintenance agent for COPD under GOLD guidelines.

Corticosteroids

Inhaled corticosteroids (ICS) such as fluticasone, budesonide, and beclomethasone enter airway epithelial cells and bind the glucocorticoid receptor. The resulting complex translocates to the nucleus and suppresses transcription of pro-inflammatory genes, including those encoding interleukin-4, interleukin-5, and interleukin-13. Systemic corticosteroids — oral prednisone or intravenous methylprednisolone — follow the same molecular mechanism but distribute throughout the body, increasing the risk profile for adverse effects including adrenal suppression, osteoporosis, and hyperglycemia.

Biologics

Biologic agents used in pulmonary medicine target the type 2 inflammatory pathway with precision. The five FDA-approved anti-type-2 biologics for severe asthma as of 2023 include:

  1. Mepolizumab — anti-IL-5 monoclonal antibody
  2. Reslizumab — anti-IL-5 monoclonal antibody
  3. Benralizumab — anti-IL-5 receptor alpha antibody
  4. Dupilumab — blocks IL-4 receptor alpha, inhibiting both IL-4 and IL-13 signaling
  5. Tezepelumab — anti-thymic stromal lymphopoietin (TSLP) antibody, active upstream of the type 2 cascade

For pulmonary fibrosis, two antifibrotic agents — pirfenidone and nintedanib — are FDA-approved. Nintedanib inhibits multiple tyrosine kinases (FGFR, VEGFR, PDGFR) involved in fibroblast proliferation, representing a mechanistically distinct category from the antibody-based biologics.

Common Scenarios

COPD exacerbation — Short-acting bronchodilators (SABA or SAMA — short-acting muscarinic antagonist) serve as rescue therapy. Systemic corticosteroids reduce exacerbation duration; a 5-day course of oral prednisone is supported by GOLD evidence-based recommendations. Antibiotics are added when bacterial infection is suspected based on sputum character and clinical criteria.

Moderate persistent asthma — GINA Step 3 therapy pairs a low-to-medium dose ICS with a LABA. The FDA's requirement for ICS/LABA co-formulation in asthma (e.g., fluticasone/salmeterol, budesonide/formoterol) emerged from black-box warning language applied to single-agent LABA prescribing.

Severe eosinophilic asthma — When blood eosinophil counts exceed 300 cells per microliter and exacerbations persist despite high-dose ICS/LABA, anti-IL-5 biologics enter the treatment pathway. Biologic selection is guided by biomarker profile: eosinophil count, fractional exhaled nitric oxide (FeNO), and allergen sensitization status.

Pulmonary hypertension — A separate pharmacological classification applies, including phosphodiesterase-5 inhibitors (sildenafil, tadalafil), endothelin receptor antagonists (ambrisentan, bosentan, macitentan), and prostacyclin analogues (epoprostenol, treprostinil). These agents are regulated under specific REMS programs administered by the FDA due to teratogenicity and hemodynamic risk.

For patients managing ongoing medication regimens at home, inhaler therapy provides detailed technique and device-specific guidance.

Decision Boundaries

The following framework reflects classification logic used in published GOLD and GINA guidelines for medication selection:

  1. Confirm diagnosis and phenotype first — Spirometry-confirmed obstruction (FEV1/FVC ratio below 0.70 post-bronchodilator per GOLD criteria) distinguishes COPD from other causes of dyspnea. Asthma diagnosis requires demonstrated variable airflow obstruction (pulmonary function tests are the reference tool).

  2. Match drug class to mechanism — Bronchodilators address structural or functional airway narrowing; corticosteroids address inflammatory airway disease; biologics address specific molecular endotypes. Using a biologic in the absence of confirmatory biomarkers is not supported by FDA label indications.

  3. Route follows severity and setting — Inhaled therapy is first-line for maintenance in stable outpatient disease. Systemic corticosteroids are reserved for acute exacerbations or conditions where inhaled delivery is anatomically or physiologically inadequate.

  4. Safety monitoring is class-specific — ICS use at high doses requires monitoring for adrenal suppression (per FDA prescribing guidance). LAMA use requires assessment of urinary retention risk in patients with benign prostatic hyperplasia. Biologic infusion protocols carry anaphylaxis monitoring requirements, and REMS programs apply to endothelin receptor antagonists.

  5. Step-down is as critical as step-up — GINA and GOLD both include explicit step-down protocols. Maintaining patients on higher-intensity therapy than disease activity warrants increases adverse event exposure without clinical benefit.

The full spectrum of pulmonary care — from initial presentation through specialist workup — is accessible through the pulmonary medicine home, which organizes resources across disease categories, diagnostic tools, and treatment pathways.

References

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)